ArticlePloS one2016
Effects of Multidrug Resistant Tuberculosis Treatment on Patients' Health Related Quality of Life: Results from a Follow Up Study.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Article
- Epidemiologic trajectories and burden of multidrug-resistant tuberculosis (MDR-TB) mortality across South Asia: An analysis of Global Burden of Disease data (1990-2023) with machine learning forecasting to 2050.Journal of clinical tuberculosis and other mycobacterial diseases · 2026Article
- Health-related quality of life and associated factors among adult tuberculosis patients in Kembata Zone, Southern Ethiopia: a mixed-methods cross-sectional study.BMC infectious diseases · 2026Article
- The effects of stigma and social support on the health-related quality of life of people with drug resistance tuberculosis in Lagos, Nigeria.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025Article
- The health-related quality of life of drug-resistant tuberculosis patients receiving treatment in Botswana.BMC infectious diseases · 2024Article
- Assessing the quality of life in patients with drug-resistant tuberculosis: a cross-sectional study.BMC pulmonary medicine · 2024Article
- Quality of life among drug-resistant tuberculosis patients on treatment in SouthWest Nigeria.African health sciences · 2024Article
- Frequency, management and impact of adverse events on treatment outcomes in patients with multidrug resistant tuberculosis in Balochistan, Pakistan.Journal of pharmaceutical policy and practice · 2024Article
- Anxiety and depression level of patients with multidrug-resistant tuberculosis (MDR-TB) in two hospitals in Banten province, Indonesia.Dialogues in health · 2023Article
- Post-TB health and wellbeing.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2023Article
- A Dual Perspective of Psycho-Social Barriers and Challenges Experienced by Drug-Resistant TB Patients and Their Caregivers through the Course of Diagnosis and Treatment: Findings from a Qualitative Study in Bengaluru and Hyderabad Districts of South India.Antibiotics (Basel, Switzerland) · 2022Article
- Article
- Health-Related Quality of Life (HRQoL) of Patients with Tuberculosis: A Review.Infectious disease reports · 2022Review
- High rate of successful treatment outcomes among childhood rifampicin/multidrug-resistant tuberculosis in Pakistan: a multicentre retrospective observational analysis.BMC infectious diseases · 2021Observational
- A Saudi Arabian Public Health Perspective of Tuberculosis.International journal of environmental research and public health · 2021Review
- Between Curing and Torturing: Burden of Adverse Reaction in Drug-Resistant Tuberculosis Therapy.Patient preference and adherence · 2021Review
- Health-Related Quality of Life in Tuberculosis Patients in Eritrea: Comparison Among Drug-Susceptible and Rifampicin/Multidrug-Resistant Tuberculosis Patients.Patient related outcome measures · 2021Article
- Prevalence and risk factors of depression in patients with drug-resistant tuberculosis in Nepal: A cross-sectional study.Journal of clinical tuberculosis and other mycobacterial diseases · 2020Article
- Comorbidities between tuberculosis and common mental disorders: a scoping review of epidemiological patterns and person-centred care interventions from low-to-middle income and BRICS countries.Infectious diseases of poverty · 2020Article
- Obstructive lung disease and quality of life after cure of multi-drug-resistant tuberculosis in Uganda: a cross-sectional study.Tropical medicine and health · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAt present, within the management of multidrug resistant tuberculosis (MDR-TB) much attention is being paid to the traditional microbiological and clinical indicators. Evaluation of the impact of MDR-TB treatment on patients' Health Related Quality of Life (HRQoL) has remained a neglected area.
objectiveTo evaluate the impact of MDR-TB treatment on patients HRQoL, and determine the predictors of variability in HRQoL along the course of treatment.
methodsA prospective follow up study was conducted at the programmatic management unit for drug resistant TB of Lady Reading Hospital Peshawar. Culture confirmed eligible MDR-TB patients were asked to self complete SF-36v2 at the baseline visit, and subsequently after the completion of 12 months of treatment and at the end of treatment. A score of <47 norm-based scoring (NBS) points on component summary measures and health domain scales was considered indicative of function impairment. General linear model repeated measures ANOVA was used examine the change and predictors of change in physical component summary (PCS) and mental component summary (MCS) scores over the time.
resultsA total of 68 out of enrolled 81 eligible MDR-TB patients completed SF-36v2 questionnaire at the three time points. Patients' mean PCS scores at the three time points were, 38.2±4.7, 38.6±4.4 and 42.2±5.2 respectively, and mean MCS were 33.7±7.0, 35.5±6.9 and 40.0±6.9 respectively. Length of sickness prior to the diagnosis of MDR-TB was predictive of difference in PCS scores (F = 4.988, Df = 1, 66), whereas patients' gender (F = 5.638, Df = 1, 66) and length of sickness prior to the diagnosis of MDR-TB (F = 4.400, Df = 1, 66) were predictive of difference in MCS scores.
conclusionDespite the positive impact of MDR-TB treatment on patients' HRQoL, the scores on component summary measures suggested compromised physical and mental health even at the end of treatment. A large multicenter study is suggested to confirm the present findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.